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Abstract 
In addition to its peripheral actions, oxytocin released within the brain is important for birth 
and essential for milk ejection. The oxytocinase enzyme (placental leucine aminopeptidase, 
P-LAP) is expressed both peripherally and centrally. P-LAP controls oxytocin degradation in 
the uterus, placenta and plasma during pregnancy, but its role in the hypothalamus is unclear. 
We investigated P-LAP expression and activity in the hypothalamus in virgin, pregnant and 
lactating rats, and its role in vivo during the milk-ejection reflex. P-LAP mRNA and protein 
were expressed in magnocellular neurons of the supraoptic (SON) and paraventricular (PVN) 
nuclei. Oxytocin neurons co-expressed P-LAP without strong subcellular co-localisation of 
oxytocin and P-LAP, indicating that they are packaged in separate vesicles. Examination of 
the intracellular distribution of oxytocin and P-LAP showed a redistribution of P-LAP to 
within 1 µm  of the plasma membrane in the somata of oxytocin neurons during lactation. 
Both P-LAP mRNA expression and hypothalamic leucyl/cystinyl aminopeptidase activity in 
the soluble fraction were higher during lactation than in late pregnant or virgin states. 
Inhibition of central enzyme activity by i.c.v. injection of amastatin in anaesthetized suckling 
mothers increased the frequency of reflex milk ejections. As hypothalamic P-LAP expression 
and activity increase in lactation, and prevention of its action mimics central oxytocin 
administration, we conclude that P-LAP regulates auto-excitatory oxytocin actions during the 
suckling-induced milk-ejection reflex. 
 
 
 
Introduction 
Oxytocin is synthesized in the somata of magnocellular neurons in four hypothalamic 
nuclei; the paired supraoptic (SON) and paraventricular nuclei (PVN). It is packaged in large 
dense-cored vesicles which are transported to axon terminals in the neurohypophysis: from 
these terminals, oxytocin is secreted into the general circulation. In the rodent, during both 
parturition and the milk-ejection reflex, the magnocellular oxytocin neurons exhibit 
intermittent, quasi-synchronous bursts of electrical activity, typically every 5-10 min, which 
trigger pulsatile oxytocin secretion from the terminals. This pulsatile mode of oxytocin 
secretion is important for the progress of  parturition and is essential for milk transfer to the 
young during lactation (1-4), and it critically depends on release of oxytocin from the somata 
and dendrites of oxytocin neurons (5). Increased somato-dendritic release of oxytocin 
precedes, and is required for, the co-ordination of bursting activity: the frequency of these 
bursts can be accelerated by i.c.v. injection of oxytocin or delayed by i.c.v. injection of an 
oxytocin antagonist (1, 6, 7).  
The availability of hormones and transmitters is regulated not only by the amount 
released but also by the rate of degradation. In the periphery, serum levels and uterine and 
placental expression of the oxytocin degrading enzyme, placental leucine aminopeptidase (P-
LAP), increase during mid- to late pregnancy (8, 9). This increased expression of P-LAP is 
thought to be important for preventing premature uterine contractions, thereby helping to 
maintain normal pregnancy to term (10, 11), and deletion of P-LAP in a transgenic mouse 
model advances the onset of birth (12). However, P-LAP also degrades vasopressin, 
angiotensin III, met-enkephalin and dynorphin (13), and central injections of the P-LAP 
inhibitor amastatin have been shown to modify drinking behavior (14, 15). 
In peripheral tissues, the enzyme is found in the same intracellular vesicles as the 
glutamate transporter GLUT4, and is activated upon translocation from the cytosol to the 
 
 
plasma membrane (16-18). Inserted into the plasma membrane, P-LAP is a membrane-
spanning protein (19), which is active in the extracellular domain. In addition, the enzyme 
can be freed from the plasma membrane into the extracellular space by sheddases (20). 
Although P-LAP is thought to be active physiologically only after insertion into the plasma 
membrane, P-LAP activity is measurable in both membrane-bound and cell associated-
soluble fractions of tissue homogenates (21). 
P-LAP was recently identified in the hypothalamus (22) and inhibition of P-LAP 
activity with amastatin has been shown to mimic the effect of exogenous oxytocin 
administration on SON neuronal activity in a hypothalamic slice preparation (23). There have 
been two conflicting reports of the effect of knocking out the P-LAP gene on parturition, one 
without effect (24), the other showing a significant shortening of pregnancy duration (12).   
In this latter study, wild-type mice given continuous subcutaneous infusion of recombinant P-
LAP showed a delay in the onset of labour.  
However, there have been no studies to determine if central P-LAP plays a role in the 
control of oxytocin-dependent activity in vivo. In this study, we first visualized P-LAP 
mRNA and protein expression in the hypothalamus, and investigated its intracellular 
distribution and co-localization with oxytocin-neurophysin using immunofluorescence. 
Pregnancy- and lactation-associated changes in hypothalamic P-LAP mRNA expression were 
analyzed by in situ hybridization, and changes in cystinyl/leucyl aminopeptidase activity in 
both membrane-bound and soluble fractions from samples of hypothalamus and posterior 
pituitary were assayed in vitro. Finally, we investigated the effect of inhibiting central P-LAP 
enzyme activity in vivo on the milk-ejection reflex.  
 
 
 
 
 
Methods 
Experimental Animals:  
Adult female Sprague-Dawley rats (initial body weight 200-280g, Bantin & Kingman, UK) 
were either used as virgins, on day 19-21 of pregnancy or during lactation (post-natal day 7-
11, day of birth: being post-natal day 1). The day of finding a vaginal plug in females caged 
singly with a male was taken as day 1 of pregnancy. Rats had ad libitum access to food and 
water and 12 h of light per day (lights on: 07:00h) and ambient temperature was on average 
20-21oC.  All procedures were carried out in accordance with UK Home Office Animals 
(Scientific Procedures) Act, 1986 legislation and were approved by the University of 
Edinburgh Ethical Committee.  
 
Collection and processing of brain tissue. 
Rats were anaesthetized  with an overdose of sodium pentobarbitone (120mg/100g body 
weight, i.p.) and perfused transcardially with heparinised (5000 U/ml; 300 ml) physiological 
saline (0.9%) followed by paraformaldehyde (4%) in 0.1M phosphate buffer (PB; pH 7.2). 
Brains were removed and post-fixed overnight in 2% paraformaldehyde and 15% sucrose in 
0.1M PB at 4oC. The tissues were cryoprotected in 30% sucrose in 0.1M PB (until brains had 
fully sunk, usually 48h). The brains were snap-frozen on dry ice then sectioned coronally at 
40 µm using a freezing microtome.  
 
Colocalization of P-LAP with oxytocin-neurophysin or GM130: 
Sections from virgin, day 22 pregnant and lactating rats (4 sections containing SON per rat, 4 
rats per group) were labelled for oxytocin-neurophysin and either P-LAP or the Golgi marker 
GM130 and visualized with fluorescent probes to analyze their subcellular co-localization 
 
 
and distribution. In brief, sections were incubated in P-LAP antibody (gift from Dr 
Tsujimoto, Riken Brain Institute; Japan; rabbit polyclonal; 1:1000) and either an oxytocin-
neurophysin antibody (PS38, a gift from Professor Hal Gainer, National Institute of 
Neurological Disorders and Stroke, National Institutes of Health, Bethesda, USA; mouse 
monoclonal; 1:5000) or GM130 antibody (BD Transduction Laboratories; mouse 
monoclonal; 1:1000), for 48h. This was followed by incubation with a biotinylated anti-rabbit 
secondary antibody (Vector Laboratories, UK, 1:500 for 2h at room temperature in the dark), 
then streptavidin conjugated-Alexa Fluor 488 (green, to visualize P-LAP) and Alexa Fluor 
568 anti-mouse secondary antibody (red, to visualize oxytocin-neurophysin or GM130; both 
Life Technologies, UK, each at 1:500). After further washing, the sections were mounted 
using a Moviol-based medium (Calbiochem, San Diego, CA, USA), supplemented with 2.5% 
DABCO (1, 4-diazabicyclo[2.2.2]octane, Sigma).  
Fluorescence signals were acquired using a Zeiss LSM510 Axiovert Confocal laser 
scanning microscope, equipped with argon/krypton lasers. Emissions from each 
fluorescently-labelled secondary antibody were acquired consecutively to ensure no bleed 
between channels. Signals were acquired at 1024x1024 pixels, using a Zeiss Plan 
NeoFLUAR 1.4 NA x63 oil-immersion objective. For intracellular co-localisation analysis, 
images of SON oxytocin neurons were taken throughout each cell at Nyquist sampling rates 
which were deconvolved using Huygens software (Scientific Volume Imaging). For each 
cell, the middle layer was identified and the image cropped to the outline of the cell, and the 
resultant image was examined using NIH Image J software to calculate the degree of co-
localization (quantified by Pearson’s co-efficient of variation). This was repeated for 15 cells 
each from virgin female, D22 pregnant and D8-11 lactating rats and data compared. Cells in 
each treatment group were averaged and compared using a one-way analysis of variation 
followed by Tukey's post-hoc test. In addition, the distributions of both the oxytocin-
 
 
neurophysin and P-LAP signals from the cell nucleus to plasma membrane were investigated 
in SON oxytocin neurons using ImageJ software. The mid-optical layer of each cell was 
separated into two layers, one for each channel (red and green). For each cell, 16 lines were 
drawn from the cell nucleus to the plasma membrane and measurements of signal intensity of 
both channels made with respect to the line distance. For each signal, the intensity of signal 
was expressed as a percentage of the total signal intensity for the length of the line. The 
measurements were binned into 1µm segments so that the normalised proportion of signal for 
oxytocin-neurophysin and P-LAP in the 1µm closest to the nucleus and 1µm closest to the 
plasma membrane for each cell could be averaged. This was repeated for 15 cells each from 
virgin female, D22 pregnant and D8-11 lactating rats and data compared. 
No fluorescent labelling was detected when primary antibodies were omitted. P-LAP (25) 
and oxytocin-neurophysin antibody specificity have been described previously (26, 27) and 
the GM130 primary antibody specificity is described on BD Transduction Laboratories 
website (catalogue number 610822).  
 
P-LAP mRNA expression  
P-LAP mRNA expression was analyzed by quantitative in situ hybridization in virgins (n=6), 
and rats on day 20-21 of pregnancy (n= 6) or day 8-9 of lactation (n=7). The litter size ranged 
from 11-18 pups (median=13) in the pregnant group and 11-15 pups (median=12) in the 
lactating group. All lactating mothers exhibited maternal behaviors including 
licking/grooming and suckling pups, and milk could be seen in the stomachs of the pups. The 
rats were killed between 10:00-12:00h and their brains removed and frozen immediately on 
dry ice, as above. Placentae were also collected from the pregnant rats for use as positive 
control and negative controls.  
 
 
 
Preparation of P-LAP probe: A rat P-LAP cDNA (28) was generously provided by Dr 
Tsujimoto (Riken Brain Institute, Japan). 35S-UTP labelled cRNA sense and antisense probes 
were synthesized from the linearized pCI-neo vector expressing a 3075 base-pair cDNA 
fragment encoding rat P-LAP. The plasmid was linearized with MluI and EcoRI and 
transcribed using T7 and T3 polymerases (Promega UK Ltd., Southampton, UK), for the 
sense and antisense riboprobes, respectively. To aid tissue penetration, the radiolabelled P-
LAP riboprobe was fragmented by alkaline hydrolysis (60oC for 20 min) and neutralized 
before hybridization.  
 
In situ hybridization : Whole brains were cryostat-sectioned coronally at 15µm and thaw 
mounted onto DNase/RNase free Poly-lysine® glass microscope slides (VWR) and stored at 
–70oC. Slides were selected from the SON and PVN for each rat and were processed by in 
situ hybridization as previously described (29). Coronal sections of placenta treated as above 
were used as positive controls (see Fig 4A  left). Brain and placenta sections serving as 
negative controls to ensure probe specificity were hybridized with 35S-UTP labelled cRNA 
sense probes (see Fig 4A right for placenta negative control). After overnight hybridization, 
the slides were rinsed briefly in 2x saline sodium citrate (SSC) and then washed 3 x 5 min in 
2x SSC at room temperature. Next, sections were incubated in buffer (1mM EDTA, 500mM 
sodium chloride, 10mM Tris, pH 7.6) containing 15µg/ml RNAse A for 60 min at 37oC. 
Sections were then briefly rinsed in 2X SSC at room temperature before further stringency 
washing (60 min each in 2x SSC at 50oC, 0.2x SSC at 55oC, then 0.2x SSC at 60oC). 
Following the post-hybridization washes tissue was dehydrated in an ascending series of 
ethanol containing 300 mM ammonium acetate and air-dried. Slides were then either exposed 
 
 
to autoradiographic film for 13 days or dipped in emulsion (K-5, Ilford, Knutsford, Cheshire, 
UK), and incubated at 4oC for 5 weeks.  
 
Quantification: After developing, fixing (Kodak D-19, Sigma; Hypam rapid fixer, Ilford) and 
counterstaining with haematoxylin and eosin, autoradiographs were quantified in emulsion-
dipped slides. The silver grain area overlying each magnocellular SON and PVN region and 
the area of each nucleus profile was measured in 9 consecutive sections per rat (NIH Image 
software, v1.62) and grain density calculated as grain area divided by nucleus profile area 
(mm2/mm2). Background measurements were made over areas adjacent to the region of 
interest and subtracted. The hybridization signal over tissue hybridized with the sense probe 
was not different from background.  
 
Aminopeptidase activity 
Both soluble and membrane-bound aminopeptidase activities were assayed for virgin (n=7), 
19-21 day pregnant (n=7) and 7-8 day lactating (n=6) rats. The rats were deeply anaesthetized 
with pentobarbitone (120mg/100g body weight, i.p) and transcardially perfused with ice-cold 
isotonic saline (4oC) for 5-10 min (~100ml) before their tissues were collected and frozen on 
dry ice. A thick coronal slice containing the hypothalamus was cut from the brain and the 
hypothalamus (including the SON and PVN, ~50mg), the pituitary was removed and the 
neurohypophysis (posterior pituitary) separated from the pars intermedia and 
adenohypophysis; the cerebral cortex was collected as a control for regional specificity. 
Samples of placenta and pregnant uterus were also collected for analysis as positive control 
tissues (20% of one placenta and ~50mg uterus containing an implantation site were collected 
from each pregnant rat).  
 
 
  Both leucyl aminopeptidase (Leu-AP) and cystinyl aminopeptidase (Cys-AP) 
activities were measured as independent and complementary indicators of oxytocinase 
activity. Activity was assayed as amount of substrate hydrolyzed by soluble or membrane-
bound fractions. To generate the two fractions, tissue samples were homogenized in ice-cold 
1ml Tris/Cl buffer (pH 7.4) for 1 min at 900 rpm and then ultra-centrifuged at 100,000g for 
30 min at 4oC. The supernatant was collected and kept overnight at 4oC until assay for 
soluble enzyme activity. The pellet was then re-homogenized in 1ml TrisCl buffer containing 
1% Triton X-100 as before and centrifuged again at 100,000g for 30min at 4oC. The 
supernatant was incubated with Biobeads (polymeric adsorbant; Biorad) for 2h at 4oC on a 
rotating shaker to capture the detergent which would inhibit aminopeptidase activity. The 
supernatant was collected and stored at 4oC overnight until assay for membrane-bound 
enzyme activity. Aliquots were analyzed for Leu-AP- and Cys-AP activity and for protein 
content. For enzyme activity, samples (and control blanks) were incubated with shaking for 
30min at 37oC with 1ml substrate solution (either 2.92mg/100ml leucyl-β-naphthylamide in 
50mM Tris/Cl buffer pH 6.0 or 5.63mg/100ml cystinyl-β-naphthylamide in 50mM phosphate 
buffer pH 7.4; both with 10% dithiothreitol and 10% fraction V bovine serum albumin, 
BSA). The reaction was stopped with 1ml 0.1M acetate buffer pH 4.2 on ice. Low (range 
2000-7000 pmole) and high (range 7000-50,000 pmole) standard curves (depending upon 
enzyme activity level), were generated by incubating increasing concentrations of 2-
naphthylamine in TrisCl buffer containing dithiothreitol and BSA as above and stopped with 
acetate buffer on ice. Fluorescence was read at 345nm excitation and 412 nm emission on a 
spectro-fluorimeter, and enzyme activity calculated by reading from the curve. Protein in the 
samples was estimated by the Bradford assay, reading the absorbance at 595nm on a 
spectrophotometer. Activity was expressed as nM substrate (Leu- or Cys-naphthylamide, 
NA) degraded/min/mg total protein. 
 
 
 
The milk ejection reflex 
The effects of i.c.v. oxytocin, which increases the frequency of the milk ejection reflex (30), 
with i.c.v. amastatin, an oxytocinase-inhibitor were compared (31, 32). Lactating (post-natal 
day 8-10, n=5) rats with at least 6 pups were separated from all but one pup overnight, and 
the following morning were anaesthetized with urethane (ethyl carbamate 1.1g/kg body 
weight, i.p.). A cannula filled with heparinized 0.9% saline was placed in the left femoral 
vein for injection of standard oxytocin solutions to calibrate the mammary gland responses. 
Saline-filled cannulae were placed in at least one of the left nipple ducts to record intra-
mammary pressure (via pressure transducers connected to a CED 1401 A/D interface 
connected to a computer). The intra-mammary pressure measurements were acquired and 
analyzed using Spike2 (v6, Spike 2 software; CED, Cambridge UK). For i.c.v. administration 
of drugs, a 21 gauge guide cannula was inserted into the left lateral cerebral ventricle (4.5 
mm from top of the skull; 0.1mm caudal and 0.6mm lateral to bregma). 1 h after completion 
of surgery, the hungry pups were placed at the nipples and allowed to suckle; further 
experimental procedures continued only after at least 6 pups were attached to the nipples. The 
sensitivity of the mammary glands to the concentration of circulating oxytocin was assessed 
using i.v. injections of 0.1, 0.25 and 0.5mU of oxytocin in isotonic saline. These exogenous 
oxytocin “pulses” convert to 0.2 ng, 0.5 ng and 1.0 ng respectively. These injections were 
repeated at the end of the experiment to verify the oxytocin-sensitivity of the mammary 
glands was unchanged and to provide dose-response curves. The dose-response curves were 
used to convert the amplitude measurements of the sharp increases in intra-mammary 
pressure to plasma concentrations of endogenous oxytocin pulses. At least 30 min after 
checking mammary gland sensitivity and recording a control period of milk ejection reflexes, 
an i.c.v. injection was made of either oxytocin (1 µmol in 2 µl artificial cerebrospinal fluid, 
 
 
aCSF) or amastatin (6 nmol in 2 µl aCSF). The milk-ejection frequency in the 15 min 
following treatment was compared to that in the 15 min pre-injection period. A second i.c.v. 
injection was not made until at least 30 min after the milk-ejection frequency returned to the 
control frequency. I.c.v cannula placement was verified post mortem after injection of dye (2 
µl 1% alcian blue dye) into the cerebral ventricles.  
 
Statistics 
Data were analyzed using SigmaStat software. Kruskal-Wallis one-way Analysis of Variance 
(ANOVA) on ranks followed by Tukey's post-hoc test was used to compare expression, co-
localization and activity analysis across the groups. Characteristics of the milk ejection reflex 
(frequency and amplitude) were compared using unpaired t-tests. P<0.05 was considered 
significant. The data shown are means ± S.E.M.  
 
 
Results 
P-LAP expression  
Immunocytochemistry revealed labelling of P-LAP in SON and PVN neurons, including both 
magnocellular and parvocellular (PVN) neurons (Fig. 1A-D). In SON and PVN 
magnocellular neurons, P-LAP immunoreactivity was observed in both the somata and the 
dendrites (Figs 1A, D and 2A [lactating], arrowheads) of labelled oxytocin neurons. P-LAP 
labelling was also observed in oxytocin-negative neurons (Fig 1D, arrows), presumed (in the 
SON) to be magnocellular vasopressin neurons. Other P-LAP labelled regions included the 
ventromedial hypothalamic nucleus, arcuate nucleus, suprachiasmatic nucleus, cortex and 
 
 
hippocampus (not shown), consistent with the previously reported distribution of P-LAP in 
the rat brain (20).   
 
Analysis of cellular co-localization with oxytocin-neurophysin or a Golgi marker  
Images of SON that were taken through deconvolution processing showed punctate P-LAP 
immunoreactivity in both oxytocin neurons and in non-oxytocin (presumptively vasopressin) 
neurons (Fig. 2). SON neurons have a subplasmalemmal cortical layer of actin (33), and 
labelling F-actin with Alexa 647-phalloidin was used to define the boundaries of individual 
somata and proximal dendrites. Each image was cropped in X- , Y- and Z-projection so that 
just the middle layer of a single cell was shown. These cropped images were then used to 
analyse P-LAP and oxytocin-neurophysin co-localisation. In cells from control and pregnant 
rats there was overlap of the areas of the cell in which P-LAP and oxytocin-neurophysin were 
seen. Although a high Person’s co-efficient of co-variance was meassured (Fig 2C), it was 
not perfect indicating that P-LAP may be present in different vesicles from those that contain 
oxytocin but that the oxytocin and P-LAP containing vesicles travel in similar parts of the 
cell cytoplasm. There was a significant descrease in the co-variance of oxytocin and P-LAP 
in lactating rats compared to virgin rats (Pearson’s coefficient of variation: virgins 0.88±0.02 
pregnant 0.79±0.03; lactating 0.66±0.05; P<0.05 lactating vs virgins by Kruskal-Wallis one-
way ANOVA on ranks; H =13.686. Fig. 2C). This may be due to the greater rate of oxytocin 
secretion from the somato-dendritic compartment during laction with perhaps the retention of 
P-LAP at the plasma membrane. 
Additional images were used to determine the colocalisation of P-LAP and the Golgi 
marker GM130 in SON magnocellular neurons (not exclusively oxytocin cells; Fig. 2B,D). 
Strong P-LAP immunoreactivity was consistently seen in the perinuclear region where the 
Golgi apparatus is typically found. Analysis of colocalization of P-LAP with GM130 showed 
 
 
no significant difference in average Pearson’s coefficient of variation among control, 
pregnant and lactating rats (Fig. 2D).  
Line analysis was used to examine the subcellular distribution of P-LAP and/or 
oxytocin-neurophysin within the soma cytoplasm, using the same mid-cell layer from 
individual oxytocin cells described above. Sixteen radiating lines were placed across the cell, 
starting at the nucleus and ending at the plasma membrane. The signal intensity in the pixels 
covered by the line and occupied by each channel in 1-µm intervals (bins) was calculated for 
each line, and those in the first (perinuclear area) and last (plasma membrane) bins were 
averaged for the 16 lines on that cell (Figs 3). In cells from lactating rats, for both oxytocin-
neurophysin and P-LAP, less of the immunoreactivity was found in the perinuclear area and 
more at the plasma membrane compared to cells from virgin controls (% oxytocin-
neurophysin in perinuclear area: virgins 23.0±2, pregnant 16.6±1, lactating 16.6±1.1; P<0.05 
vs virgins; H=24.2; %oxytocin-neurophysin near plasma membrane: virgins 9.9±0.8, 
pregnant 8.6±0.95, lactating 15.5±1.2; P<0.05 vs lactating; H=61.3;. % P-LAP in perinuclear 
area: virgins 25.11±1.8, pregnant 20.2±1, lactating 20.1±1; P<0.05 vs lactating; H=20.7; %P-
LAP near plasma membrane: virgins 10.2±0.7; pregnant 8.8±0.8; lactating 14.3±0.9; P<0.05 
vs lactating, H=52.9; Fig. 3). Cells from pregnant rats showed an intermediate state between 
virgin and lactating (no significant difference to the lactating group in the perinuclear area, 
but less than in the virgin group for both oxytocin and P-LAP). Conversely, at the plasma 
membrane there was no significant difference compared to the virgin group, but significantly 
less of the oxytocin and P-LAP immunoreactivity was at the plasma membrane than in the 
lactating group. All of this suggests that during lactation when there is an increased demand 
on somato-dendritic secretion, there is a re-distribution of both oxytocin and P-LAP from the 
pernuclear area to the plasma membrane. 
 
 
 
Effect of pregnancy and lactation on P-LAP mRNA expression in the hypothalamus 
Strong P-LAP mRNA hybridization was observed in the SON and PVN (Fig. 4B, C), 
although expression was less dense than in the placenta (Fig. 4A, left anti-sense positive 
control). There was a complete lack of P-LAP mRNA hybridisation in the placental sense 
negative control (Fig 4A, right). As with the immunocytochemical labelling, hybridization 
was observed in other hypothalamic regions, including the ventromedial hypothalamus, 
arcuate nucleus and suprachiasmatic nucleus (not shown). Some non-hypothalamic brain 
areas including the cortex also exhibited hybridization. In the magnocellular PVN, grain 
density was greater in lactating rats than in virgin or late-pregnant rats (both P<0.05, 
F=5.841, d.f.= 16; Fig 4D). In the SON there were no significant differences in grain density 
with reproductive status (virgin: 0.77±0.07; pregnant: 0.96±0.2; lactating: 0.63±0.08 
mm2/mm2; Fig. 4C).  
 
Effect of pregnancy and lactation on aminopeptidase activity 
Measurements of Cys-AP activity and Leu-AP activity showed a generally consistent pattern: 
lactating rats had higher mean levels of activity than virgins in both the posterior pituitary 
and hypothalamus, for both Cys-AP and Leu-AP activity, in the soluble fractions (posterior 
pituitary: Cys-AP, P<0.05, F=7.19; Leu-AP, P<0.05, F=4.17; hypothalamus: Cys-AP, 
P<0.05, F=20.07; Leu-AP, P<0.05, F=8.1; Fig. 5). The enzyme activity in membrane-bound 
fractions was also significantly higher in lactating rats for Cys-AP and Leu-AP activity in the 
posterior pituitary, but not hypothalamus (posterior pituitary: Cys-AP, P=0.09, F=2.7; Leu-
AP, P<0.05, F=13.49; hypothalamus: Cys-AP, P<0.05, F=4.31; Leu-AP, P=0.47, F=0.78; 
Fig. 5). In hypothalamic fractions, the mean level of Leu-AP activity consistently exceeded 
that of CysAP activity, whereas the converse was the case for posterior pituitary fractions.  
 
 
These differences with reproductive state were regionally specific. In the cerebral 
cortex,  there were no significant differences between groups for Leu-AP or Cys-AP activity 
in the soluble fraction (Leu-AP: virgin 19768±2123; pregnant 13103±2049; lactating 
18639±4247 NA/min/mg total protein; Cys-AP: virgin 4400±330; pregnant 4224±549; 
lactating 5508±874 NA/min/mg total protein). In the membrane-bound fraction, there was 
more Leu-AP activity in the cortex in pregnant rats (15214±1358) than in virgin (4728±514) 
or lactating rats (917±822 NA/min/mg protein; both P<0.05, F=40.14) but no significant 
differences in the membrane-bound fraction (virgin 2512±217; pregnant 3243±702; lactating 
2516±490 NA/min/mg protein). 
 
Uterus: Similar to previous reports (8), Leu-AP activity in the soluble fraction of the uterus 
was similar between groups (data not shown), but there was more membrane-bound activity 
in pregnant rats than in virgin rats (28356±3408 and 8344±964 NA/min/mg total protein, 
respectively, t-test P<0.05). 
 
Effect of blocking oxytocinase activity on the milk-ejection reflex 
Intramammary pressure recordings were made in anaesthesised suckling mothers. Central 
amastatin administration (6 nmole in 2µl) rapidly increased the frequency of the milk-
ejection reflex to a similar extent as oxytocin (1 µmole in 2µl saline i.c.v., Fig. 6). The 
frequency of milk ejections significantly increased by 224±15% after i.c.v. oxytocin and by 
268±29% after i.c.v.amastatin (P<0.05, t-test, n= 5). However, the average amplitude of 
intramammary pressure did not significantly change with either oxytocin or amastatin 
treatment. The intramammary pressure changes in response to known concentrations of 
intravenously applied oxytocin were used to calculate the amount of oxytocin released during 
each milk ejection reflex. Increasing central oxytocin either by icv injection of oxytocin or 
 
 
amastain resulted in a significant increase in the amount of oxytocin released from the 
pituitary (from 1.5±0.09 to 3.5±0.49 and 0.8±0.04 to 3.1±0.23 pmoles respectively, P<0.05, 
t-test).  
 
Discussion  
In the present study, we showed that an enzyme capable of degrading oxytocin (P-LAP) is 
expressed in the magnocellular oxytocin neurons of the SON and PVN, the main location of 
oxytocin synthesis. We found that P-LAP mRNA expression in the PVN is significantly 
increased during lactation, a time when extracellular oxytocin plays a key role in regulating 
milk ejection and maternal behavior, and this increase is accompanied by increases in the 
hypothalamic and posterior pituitary gland activity of leucyl and cystinyl aminopeptidases.  
It seems unlikely that the measured aminopeptidase activity in posterior pituitary and 
hypothalamic extracts is solely attributable to P-LAP, because of the apparent tissue specific 
divergence in the leucyl aminopeptidase activity and cystinyl aminopeptidase activity. 
Nevertheless, P-LAP evidently plays an important role in regulating central oxytocin 
availability,  including regulating of the pattern of oxytocin neuronal firing during lactation. 
However, we did not find a significant increase in either P-LAP mRNA in the SON or PVN, 
nor in hypothalamic P-LAP activity in late-pregnant rats. This is perhaps not unexpected 
given that the oxytocin neurons are relatively quiescent in late pregnancy (which is proposed 
to minimise the risk of preterm birth) via an endogenous inhibitory opioid mechanism 
induced by allopregnanolone (29, 34, 35). The present data also indicate that altered 
hypothalamic P-LAP activity/expression in pregnancy is not involved in preventing preterm 
birth. However, it is likely that the action of P-LAP at other sites e.g. the uterus does play an 
important role given that the onset of labour is advanced in P-LAP knockout mice (12).   
 
 
Oxytocinase enzyme activity in the hypothalamus was consistently higher in lactating 
rats than in virgins, and it seems likely that this alters the regulation of central oxytocin 
actions. P-LAP mRNA expression was also higher in the PVN in lactation, but we did not 
observe a similar increase in the SON. However, most of the neurons in the SON make 
vasopressin, not oxytocin, whereas oxytocin is relatively more abundant in the PVN (36), and 
as P-LAP is expressed in both oxytocin neurons and vasopressin neurons, it may simply be 
that an increase in P-LAP expression in SON oxytocin neurons is hidden within a larger 
signal from vasopressin neurons (37).  
The immunocytochemical studies were consistent with changes in P-LAP trafficking 
in oxytocin neurons, but do not provide evidence of expression level. P-LAP 
immunoreactivity was present in the somata and dendrites of all oxytocin neurons, and in 
vitro enzyme activity was measurable in the posterior pituitary, where the axons terminate. 
Using double immunofluorescence we observed punctate labelling of P-LAP within neurons, 
which suggests that it is packaged in vesicles, consistent with reports of P-LAP packaged in 
GLUT4- containing vesicles in peripheral tissues (38, 39). Colocalization of the enzyme with 
the Golgi marker GM130 was high, and particularly strong in the perinuclear region of the 
cell where the Golgi apparatus is located. This is also consistent with reports of a population 
of GLUT4 vesicles containing P-LAP being tethered at the Golgi apperatus by the protein 
tankyrase (40).  
Although degradation of oxytocin in the brain has been studied previously (41),  the 
sites, rate and regulation of degradation have been poorly characterized. As oxytocin 
concentrations are generally higher in the CSF than in plasma, and are present there at 
physiologically active concentrations, it is clear that a significant amount of centrally released 
oxytocin evades local degradation to diffuse (or be conveyed) from its release sites in the 
brain to the ventricles.  Oxytocin in the CSF has a half-life of about 20 min, indicating that its 
 
 
clearance from CSF is mainly by bulk flow rather than enzymatic degradation (42). However, 
in the CSF, concentrations of oxytocin-associated neurophysin exceed those of oxytocin by a 
factor of about 50, although these are co-secreted in equimolar amounts. As neurophysin is 
considered to not be degraded (41), there is clearly substantial degradation of oxytocin en 
route through the extracellular space to the CSF.  
Finally, blocking central oxytocinase action revealed a physiological role for 
oxytocinase in controlling the milk-ejection reflex, indicating that degradation of oxytocin 
contributes to the control of oxytocin availability to its receptors within the hypothalamus. 
These data extend previous reports that blocking aminopeptidase action in vitro modifies 
oxytocin neuron electrical activity (23).  Oxytocin has important effects on a variety of social 
behaviours (43), and it has been widely suggested that it may be a valuable therapetic target 
in treating autism (44). Furthermore, decreased oxytocinase activity in the amygdala 
following stress indicates a role in modulating oxytocin actions in the context of stress 
responses (45). Thus our present observations highlight the possibility of targetting central 
oxytocin actions by targetting the enzymes that are active in its degradation. 
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Figure Legends 
Figure 1.  
A,B) Double immunofluorescent labelling for P-LAP (green) and oxytocin-neurophysin (red) 
in the PVN of a virgin female rat. The merged images (C,D) reveal co-localization (orange, 
arrow lines) of P-LAP in oxytocin-neurophysin neurons and dendrites and presence in 
adjacent neurons (hollow arrows). Scale bars A-C: 100µm, D: 20µm. 
 
Figure 2.  
Images of cellular localization of either (A) oxytocin-neurophysin (red) or (B) GM130 (Golgi 
marker, red)  with P-LAP (green) and phalloidin (F-actin marker, blue) and merged images in 
SON neurons from virgin, pregnant and lactating rats. Note that P-LAP is also found in 
presumptive vasopressin neurons (VP). Quantification of covariance data of P-LAP and 
oxytocin-neurophysin (C) or GM130 (D) using Pearson’s coefficient values from SON 
neurons in virgin, pregnant and lactating rats (mean +/- SEM, N=15 per group) Intracellular 
distribution of oxytocin-neurophysin (E) or P-LAP (F) in the treatment groups. Scale bars = 
10µm, *P<0.05 compared to virgin control, one-way ANOVA followed by Tukey’s post-hoc 
test.   
 
Figure 3.  
A) Example images of an oxytocin neuron (from a lactating rat) with immunoreactivity for 
oxytocin-neurophysin (red) and P-LAP (green). The outline of the cell (drawn in blue) was 
defined using the phalloidin signal. The yellow line is an example of one of the 16 lines 
drawn from the nucleus to plasma membrane and used to measure the signal intensity of each 
 
 
channel along each line (shown here in white above the line) (N=15 cells/group). Scale bar = 
5µm. B) The signal intensities for each channel within 1µm either to the nucleus or the 
plasma membrane are expressed as a percentage of the total of each line and the averages 
plotted for oxytocin and P-LAP from the three groups.  *P<0.05 compared to virgins, one-
way ANOVA followed by Tukey’s post-hoc test.   
 
Fgure 4.  
A) Light photomicrographs of film autoradiographs of placenta processed for P-LAP mRNA 
by in situ hybridization showing the antisense (left) and sense control (right). B) Light 
photomicrographs of autoradiographs of the hypothalamus showing hybridization of P-LAP 
mRNA in the SON and PVN. Quantification of grain density of P-LAP mRNA in the (C) 
SON and (D) magnocellular sub-division of the PVN from virgin, pregnant and lactating rats 
(mean +/- SEM). Scale bars = 200µm. One way ANOVA followed by Tukey’s post-hoc test, 
*P<0.05 vs. virgin and pregnant groups. F=5.841, d.f. = 16. N= 6, 6 and 5 for virgin, 
pregnant and lactating groups respectively. 
 
Figure 5.  
Aminopeptidase activity in soluble and membrane-bound fractions of (A) hypothalamus or 
(B) posterior pituitary tissue from virgin, pregnant and lactating rats (mean +/- SEM, n=6-7 
per group). One-way ANOVA followed by Tukey’s post-hoc test, *P<0.05 vs virgins.  
 
Figure 6.  
Examples of intramammary pressure (i.m.p.) recordings of the milk-ejection reflex (MER) 
before and after i.c.v. (A) oxytocin (1pmole in 2µl) or (B) amastatin (P-LAP inhibitor; 6 
nmole in 2µl). Sharp increases in i.m.p. during suckling reflect milk ejections caused by 
 
 
action of a pulse of oxytocin secreted by the posterior pituitary as a result of synchronised 
burst-firing of magnocellular oxytocin neurones. Burst-firing, and hence milk ejections are 
facilitated by auto-excitatory actions of oxytocin released in the SON and PVN: thus  i.c.v. 
oxytocin triggers milk ejections, and amastatin acts similarly. Scale bar 10min. C) The 
frequency, but not the average amplitude, of the MER after i.c.v. oxytocin or amastatin was 
significantly greater (P<0.05, t-test). Using a dose-response curve of the amplitude of 
intramammary pressure changes in response to known concentrations of oxytocin given i.v., 
there was a significant increase in oxytocin release after i.c.v. injection of oxytocin or 
amastatin (P<0.05, t-test , n=5). 
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